Brief: Vaccitech PLC Announces Positive Data for Study in People with Chronic Hepatitis B
28/03/2023 15:51
March 28 (Reuters) - Vaccitech PLC VACC.O :
* VACCITECH PLC - POSITIVE TOPLINE FINAL DATA FOR HBV002
STUDY IN
PEOPLE WITH CHRONIC HEPATITIS B
* VACCITECH PLC - COMPLETED PHASE 1B/2A TRIAL OF VTP-300 MET
ITS
PRIMARY AND SECONDARY ENDPOINTS
* VACCITECH PLC - THERE WERE NO INCIDENTS OF GRADE 3 ADVERSE
EVENTS OR SERIOUS ADVERSE EVENTS RELATED TO VTP-300
Source text for Eikon: ID:nGNX8Tz5wD
Further company coverage: VACC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing